Neonatal Hyperbilirubinemia: Evaluation and Treatment.

Area of Science:

• Neonatal Medicine
• Pediatrics
• Clinical Practice Guidelines

Background:

• Neonatal jaundice due to hyperbilirubinemia is a common condition, typically benign.
• Kernicterus, a rare but severe form of brain damage, occurs at higher bilirubin levels than previously thought, especially in premature infants or those with hemolytic diseases.

Purpose of the Study:

• To evaluate the effectiveness of universal neonatal hyperbilirubinemia screening.
• To analyze the updated 2022 American Academy of Pediatrics (AAP) clinical practice guidelines.
• To assess the risks and benefits of phototherapy in managing neonatal jaundice.

Main Methods:

• Review of the 2022 AAP clinical practice guideline for neonatal hyperbilirubinemia.
• Analysis of evidence regarding kernicterus incidence and bilirubin thresholds.
• Evaluation of phototherapy's impact on exchange transfusion rates and adverse effects.

Main Results:

• Universal screening may lead to increased unnecessary phototherapy without proven reduction in kernicterus.
• New AAP nomograms recommend higher phototherapy thresholds based on gestational age and risk factors.
• Phototherapy, while reducing exchange transfusions, carries potential adverse effects and can disrupt breastfeeding.

Conclusions:

• Individualized assessment of risk factors and bilirubin levels is crucial for managing neonatal jaundice.
• Phototherapy should be reserved for newborns exceeding current AAP hour-specific nomogram thresholds.
• Further evidence is needed to support universal screening's benefit in reducing kernicterus incidence.